Abstract: The present invention discloses a new strain of Streptomyces sp. BICC 7522, its variants or mutants and use of the strain for the production of macrolides, process of production and purification of microlides.

Abstract: The present invention relates to variants of a parent ?-amylase, which parent ?-amylase (i) has an amino acid sequence selected from the amino acid sequences shown in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, and SEQ ID No.

Abstract: The present invention relates to variants of a parent ?-amylase, which parent ?-amylase (i) has an amino acid sequence selected from the amino acid sequences shown in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, and SEQ ID No.

Abstract: The present invention is directed to methods and compositions for microbial based production of pravastatin. The compositions of the invention include novel strains of microorganisms that are capable of efficiently hydroxylating compactin (ML-236 B) resulting in production of pravastatin. In particular, the microorganisms of the invention are genetically engineered to express both cytochrome P-450 and the fdxshe or fdxshe-like protein. The invention further relates to the use of such microorganisms in processes designed for production of pravastatin for use in treatment of disease such as hypercholesterolemia and hyperlipidemia.

Abstract: The present invention is directed to methods and compositions for microbial based production of pravastatin. The compositions of the invention include novel strains of microorganisms that are capable of efficiently hydroxylating compactin (ML-236 B) resulting in production of pravastatin. In particular, the microorganisms of the invention are genetically engineered to express both cytochrome P-450 and the fdxshe or fdxshe-like protein. The invention further relates to the use of such microorganisms in processes designed for production of pravastatin for use in treatment of disease such as hypercholesterolemia and hyperlipidemia.

Abstract: The present invention provides compounds characterized by the formula (I), where each of the substituent radicals is described in the specification. The invention also describes the use of said compounds in the treatment of various diseases, including: cancer or tumoral processes in general, Paget's disease, hypercalcaemia, hypercalciuria and neurological diseases (inter alia, Parkinson's, Alzheimer's, Huntington's).

Abstract: The present invention provides a protein comprising the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3 (except for proteins of the amino acid sequences as shown in SEQ ID NOS: 4 to 6), and a process for industrially advantageously producing a compound that inhibits HMG-CoA reductase and has an action to decrease serum cholesterol, using DNA encoding the protein comprising the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3 (except for DNA encoding the protein comprising the amino acid sequence as shown in SEQ ID NO: 4).

Abstract: The present invention relates to the fields of microbiology and vaccine technology, and concerns the development of a vaccine capable of conferring immunity to group B Streptococcus infections. More particularly, the present invention relates to a novel fusion protein, comprising N-terminal region fragments of group B Streptococcus surface proteins, which confers immunity to invasive strains of the group B Streptococcus. It further pertains to an isolated nucleotide sequence encoding said fusion protein; a vector; a host cell; a vaccine; and a method for preventing or treating a group B Streptococcus infection.

Abstract: The present invention relates to a polypeptide capable of increasing the production of L-methionine in a microorganism. In particular, the present invention relates to an YgaZ and YgaH polypeptide or a complex thereof, referred to herein as YgaZH polypeptide, which are novel putative L-methionine exporters, polynucleotides encoding the same, a recombinant vector comprising the polynucleotide, a microorganism transformed with the recombinant vector, and a method for producing L-methionine and/or S-adenosyl-methionine, comprising the steps of culturing the transformed microorganism to produce L-methionine and/or S-adenosyl-methionine, and isolating L-methionine and/or S-adenosyl-methionine.

Abstract: In the present invention, a recombination of gene groups of nemadectin aglycon biosynthesis is performed for obtaining C-13 hydroxylnemadectin, to which sugar groups can be attached, and a production strain which produces C-13 hydroxylnemadectin is produced. Further, C-13 glycosylnemadectin producing strain is prepared by introducing aveBI-BVIII genes involving glycosidation of avermectin and biosynthesis of oleandrose. As described, C-13 hydroxylnemadectin and C-13 glycosidated nemadectin can be obtained effectively by using the producing strain prepared by means of the molecular genetic technology, and improvement in the biological activity thereof can be expected.

Abstract: The invention relates to recombinant polyketide synthase enzymes, polyketide modifying proteins, and other proteins involved in polyketide biosynthesis or function. The invention provides domains of geldanamycin and herbimycin polyketide synthases, polynucleotides that encode such enzymes, and to host cells in which such encoding polynucleotides can be advantageously expressed.

Abstract: The present invention claims an isolated polypeptide having L-amino-acid-N-acyl transferase enzymatic activity and a modified microorganism in which this enzyme is overexpressed. Substrates of said enzyme include mainly methionine and their derivatives or analogs. Overexpression in sulphur-containing amino acid producing microorganisms permits the production of large amounts of N-acylated sulphur-containing amino acids. The isolation of the N-acylated sulphur-containing amino acids from the fermentation medium is also claimed.

Abstract: Disclosed is an isolated nucleotide sequence encoding an enzyme catalyzing biosynthesis of SAM (SAM-s) and its amino acid sequence. Also, the present invention provides a method for mass production of a useful secondary metabolite including antibiotics using the isolated nucleotide sequence and SAM, where SAM acts as a methyl group donor.

Abstract: Disclosed herein are compositions comprising an alpha-amylase enzyme obtained from Bacillus sp. no. 195, and methods of using the enzyme to clean surfaces and textiles. Also disclosed are variants of the enzyme with different signal sequences.

Abstract: This disclosure describes the molecular cloning of an enduracidin biosynthetic gene cluster from Streptomyces fungicidicus, and characterization of individual genes in the gene cluster and the proteins encoded thereby. An enduracidin gene cluster is located within a 116 kilobases genetic locus and includes 25 open reading frames (ORFs). An additional 23 ORFs flank the disclosed enduracidin biosynthetic gene cluster Enduracidin analogs and a method for producing them by manipulation of the enduracidin gene cluster and specific genes therein are also disclosed.

Abstract: Variants of Bacillus sp. TS-23 strain alpha-amylases exhibit improved enzymatic performance, including increased themostability, reduced calcium dependence, increased washing/cleaning performance, and baking ability. Compositions comprising these variants are useful in methods of starch processing, starch liquefaction, fermatation, starch saccharification, cleaning, laundrying, textile desizing, baking, and biofilm removal.

Abstract: The disclosure describes the production of anticancer agent LL-D45042, having the structure: by fermentation, to methods for the recovery and concentration of this anticancer agent from crude solutions, and to processes for the purification of this anticancer agent as well as a new microorganism of the species Streptomyces hygroscopicus LL-D45042 and mutants thereof useful in the preparation of this compound.

Abstract: The present invention provides a novel family of polypeptides which are ligand-gated channel receptor accessory molecules or ligands, denoted Lynx. This invention provides an isolated polypeptide comprising an amino acid sequence of a Lynx polypeptide in which the amino acid sequence is set forth in SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:15, including fragments, mutants, variants, analogs, homologs, or derivatives, thereof. This invention further provides an isolated immunogenic polypeptide comprising an amino acid sequence of a Lynx polypeptide and relates to antibodies of Lynx polypeptides and the use of such antibodies. The invention provides an isolated nucleic acid encoding a polypeptide comprising an amino acid sequence of a Lynx polypeptide. This invention provides pharmaceutical compositions and diagnostic and therapeutic methods of use of the isolated polypeptides and nucleic acids of the present invention.

Abstract: The present invention relates to microorganisms and methods for producing methionine by reactivation of the MetH enzyme.

Abstract: This invention relates to methionine producing recombinant microorganisms. Specifically, this invention relates to recombinant strains of Corynebacterium that produce increased levels of methionine compared to their wild-type counterparts and further to methods of generating such microorganisms.

Abstract: The invention provides, biologically active spinosyns, hybrid spinosyn polyketide synthases capable of functioning in Saccharopolyspora spinosa to produce the spinosyns, and methods of controlling insects using the spinosyns.

Abstract: The present invention includes cell based systems and methods for production of hyaluronate unsaturated disaccharide. The methods and systems include the use of a host cell that produces hyaluronic acid transformed with an expression vector encoding a recombinant chondroitinase AC. Expression of chondroitinase AC in the presence of native hyaluronic acid results in digestion of hyaluronic acid into multiple units of hyaluronate unsaturated disaccharide, which can then be isolated.

Abstract: The present invention relates to the biosynthesis of polyketides and derives from the cloning of nucleic acids encoding a polyketide synthase and other associated proteins involved in the synthesis of the polyketide borrelidin. Materials and Methods including enzyme systems, nucleic acids, vectors and cells are provided for the preparation of polyketides including borrelidin and analogues and derivatives thereof. Novel polyketide molecules are also provided.

Abstract: The present invention relates to variants of a parent ?-amylase, which parent ?-amylase (i) has an amino acid sequence selected from the amino acid sequences shown in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3, and SEQ ID No.

Abstract: From a bacterial strain isolated from an environmental sample, after enrichment in medium containing 1-butanol as the carbon source, a new enzyme with butanol dehydrogenase activity was identified. The enzyme can convert butyraldehyde to 1-butanol, isobutyraldehyde to isobutanol, as well as 2-butanone to 2-butanol and thus is useful for biosynthesis of butanol in recombinant microbial hosts producing these substrates. The encoding gene, named sadB, was isolated from the strain identified as an isolate of Achromobacter xylosoxidans.

Abstract: This invention relates to a novel farnesylated dibenzodiazepinone, named ECO-04601, its pharmaceutically acceptable salts and derivatives, and to methods for obtaining such compounds. One method of obtaining the ECO-04601 compound is by cultivation of a novel strain of Micromonospora sp., 046-ECO11; another method involves expression of biosynthetic pathway genes in transformed host cells. The present invention further relates to Micromonospora sp. strain 046-ECO11, to the use of and its pharmaceutically acceptable salts and derivatives as pharmaceuticals, in particular to their use as inhibitors of cancer cell growth, bacterial cell growth, mammalian lipoxygenase, and to pharmaceutical compositions comprising ECO-04601 or a pharmaceutically acceptable salt or derivative thereof. Finally, the invention relates to novel polynucleotide sequences and their encoded proteins, which are involved in the biosynthesis of ECO-04601.

Abstract: The present invention provides an improved method for the biological production of 1,3-propanediol from a fermentable carbon source in a single microorganism. In one aspect of the present invention, an improved process for the conversion of glucose to 1,3-propanediol is achieved by the use of an E. coli transformed with the Klebsiella pneumoniae dha regulon genes dhaR, orfY, dhaT, orfX, orfW, dhaB1, dhaB2, dhaB3, and orfZ, all these genes arranged in the same genetic organization as found in wild type Klebsiella pneumoniae. In another aspect of the present invention, an improved process for the production of 1,3-propanediol from glucose using a recombinant E. coli containing genes encoding a G3PDH, a G3P phosphatase, a dehydratase, and a dehydratase reactivation factor compared to an identical process using a recombinant E. coli containing genes encoding a G3PDH, a G3P phosphatase, a dehydratase, a dehydratase reactivation factor and a 1,3-propanediol oxidoreductase (dhaT).

Abstract: The present invention relates especially to a DNA fragment that is obtainable from the gene cluster within the genome of streptomycete that is responsible for elaiophylin biosynthesis and that contains at least one gene or a part of a gene that codes for a polypeptide that is involved directly or indirectly in the biosynthesis of elaiophylin and to methods of preparing said DNA fragment. The present invention relates furthermore to recombinant DNA molecules containing one of the DNA fragments according to the invention and to the plasmids and vectors derived therefrom. Also included are host organisms transformed with the said plasmid or vector DNA.

Abstract: The present invention relates to the use of cells containing in their genome a specific DNA molecule, as cytopathic agents able to inhibit the proliferation of cells, when these proliferative cells are contacted with the cells containing the above-mentioned DNA molecule.

Abstract: Variants of B. licheniformis alpha-amylase exhibit improved enzymatic performance, including increased themostability and reduced calcium dependence. Compositions comprising the variants are useful in methods of starch processing, starch liquefaction, fermatation, starch saccharification, cleaning, laundrying, textile desizing, baking, and biofilm removal. The nucleic acids encoding the variants are also disclosed.

Abstract: The present invention relates to a polynucleotide encoding an enzyme having carboxyl esterase [E.C. 3.1.1.

Abstract: The invention relates to novel polyenes having formula (I), wherein: R1 represents alkyl C1-C3; and R2 represents a functional group selected from CH3— or CONH2— (methyl- or primary amide-). The aforementioned polyenes have a biocide action on organisms comprising cell membranes that contain ergosterol, e.g., fungi or parasites. Said compounds can be obtained using a method that consists in cultivating a producing micro-organism under conditions that enable the production thereof. In addition, the invention also relates to a mechanism for the in vitro production of amidated polyenes, consisting in incubating carboxylated polyenes with cell-free extracts (or proteinaceous fractions) of the producers of same in the presence of ATP/Mg++ and an amide- group donor compound (preferably glutamine).

Abstract: The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.

Abstract: A genetically modified microorganism capable of directly producing a 16-hydroxylated macrolide compound; and a process for producing a 16-hydroxylated macrolide compound using the microorganism. Specifically, a genetically modified microorganisms having DNA encoding a polypeptide involved in the biosynthesis of a macrolide compound pladienolide and DNA encoding a polypeptide having a pladienolide 16-hydroxylase activity; and a process for producing a 16-hydroxylated macrolide compound comprising the steps of culturing the genetically modified microorganism in a culture medium and collecting a 16-hydroxylated macrolide compound from the culture medium.

Abstract: Bacterial polynucleotides and polypeptides are provided in which the polypeptides have a dehydrogenase activity, such as an alcohol dehydrogenase (ADH) activity, an uronate, a 4-deoxy-L-erythro-5-hexoseulose uronate (DEHU) ((4S,5S)-4,5 dihydroxy-2,6-dioxohexanoate) hydrogenase activity, a 2-keto-3-deoxy-D-gluconate dehydrogenase activity, a D-mannuronate hydrogenase activity, and/or a D-mannnonate dehydrogenase activity. Methods, enzymes, recombinant microorganism, and microbial systems are also provided for converting polysaccharides, such as those derived from biomass, into suitable monosaccharides or oligosaccharides, as well as for converting suitable monosaccharides or oligosaccharides into commodity chemicals, such as biofuels. Commodity chemicals produced by the methods described herein are also provided.

Abstract: The present invention relates to a method of targeting a protein of interest to an intracellular hydrophobic inclusion body of a bacterial cell by means of a fusion protein comprising a hydrophobic targeting peptide operatively linked with said protein of interest; methods of microbial production of a lipophilic compound of interest by means of a recombinant bacterial host comprising intracellular inclusion bodies having at least one enzyme which is involved in the biosynthesis of said lipophilic compound targeted to said inclusion bodies; as well as corresponding fusion proteins, coding sequences, expression vectors and recombinant hosts.

Abstract: Host cells comprising recombinant vectors encoding the FK-520 polyketide synthase and FK-520 modification enzymes can be used to produce the FK-520 polyketide. Recombinant DNA constructs comprising one or more FK-520 polyketide synthase domains, modules, open reading frames, and variants thereof can be used to produce recombinant polyketide synthases and a variety of different polyketides with application as pharmaceutical and veterinary products.

Abstract: Described herein is a novel member of the prostanoid receptor family, a guinea pig prostaglandin D2 receptor. Described are the receptor, the nucleic acid that encodes it, and various uses for both.

Abstract: Recombinant nucleic acids that encode all or a portion of the epothilone polyketide synthase (PKS) are used to express recombinant PKS genes in host cells for the production of epothilones, epothilone derivatives, and polyketides that are useful as cancer chemotherapeutics, fungicides, and immunosuppressants.

Abstract: The invention provides a method of producing acrylic acid. The method includes contacting fumaric acid with a sufficient amount of ethylene in the presence of a cross-metathesis transformation catalyst to produce about two moles of acrylic acid per mole of fumaric acid. Also provided is an acrylate ester. The method includes contacting fumarate diester with a sufficient amount of ethylene in the presence of a cross-metathesis transformation catalyst to produce about two moles of acrylate ester per mole of fumarate diester. An integrated process for process for producing acrylic acid or acrylate ester is provided which couples bioproduction of fumaric acid with metathesis transformation. An acrylic acid and an acrylate ester production also is provided.

Abstract: The present invention relates to a protein derived from a microorganism belonging to the genus Bacillus, which has an activity of hydroxylating a compound represented by the formula (I-a): wherein R1 represents a hydrogen atom, a substituted or unsubstituted alkyl, or an alkali metal, and R2 represents a substituted or unsubstituted alkyl or a substituted or unsubstituted aryl, or a ring-closed lactone form thereof; a DNA encoding the protein; and a recombinant DNA comprising the DNA.

Abstract: The invention relates to genes involved in the biosynthesis of thiocoraline and to the heterologous production of same. According to the invention, the cluster of genes responsible for the biosynthesis of thiocoraline was identified and cloned. Said cluster of genes can be used in the heterologous production of thiocoraline which has an antitumor and antibacterial activity.

Abstract: Provided are microorganisms that catalyze the synthesis of biofuels from a suitable substrate such as glucose. Also provided are methods of generating such organisms and methods of synthesizing biofuels using such organisms. Provided are microorganisms comprising non-naturally occurring metabolic pathway for the production of higher alcohols.

Abstract: Certain aspects of this disclosure relate to an isolated protease, and cleaning compositions containing the same. In some embodiments, the protease may comprise an amino acid sequence that is at least 80% identical to the wild type Streptomyces 1AG3 protease. Isolated nucleic acid encoding the subject protease, recombinant nucleic acid containing the same and host cells containing the recombinant nucleic acid are also provided.

Abstract: The present invention relates to hybrid glycosylated products, and in particular, to natural products such as polyketides and glycopeptides, and to processes for their preparation. The invention is particularly concerned with recombinant cells in which a cloned microbial glycosyltransferase can be conveniently screened for its ability to generate specific glycosylated derivatives when supplied with polyketide, peptide, or polyketide-peptides as substrates. The invention demonstrates that cloned glycosyltransferases when rapidly screened for their ability to attach a range of activated sugars to a range of exogenously supplied or endogenously generated aglycone templates, show a surprising flexibility towards both aglycone and sugar substrates, and that this process allows the production of glycosylated polyketides in good yield.

Abstract: A polyketide synthase complex composed of polyketide synthase with 15 total modules, a non-ribosomal peptide synthetase with 1 module, and a cytochrome P450 hydroxylase is described. Also provided are novel Streptomyces species and methods of modified Streptomyces species. Further described are novel compounds, 36-ketomeridamycin, C9-deoxomeridamycin, and C9-deoxoprolylmeridamcyin and uses thereof.

Abstract: Provided are nucleic acid molecules comprising at least a functional fragment of the capreomycin biosynthetic gene cluster, polypeptides encoded by the cluster and recombinant host cells transformed with any of the nucleic acid molecules disclosed herein. Various methods using any of the vectors or expression cassettes that encode one or more of the gene products of the cluster are provided for heterologous production of capreomycin and capreomycin derivatives.

Abstract: This invention relates to a novel farnesylated dibenzodiazepinone, named ECO-04601, its pharmaceutically acceptable salts and derivatives, and to methods for obtaining such compounds. One method of obtaining the ECO-04601 compound is by cultivation of a novel strain of Micromonospora sp., 046-ECO11; another method involves expression of biosynthetic pathway genes in transformed host cells. The present invention further relates to Micromonospora sp. strain 046-ECO11, to the use of ECO-04601 and its pharmaceutically acceptable salts and derivatives as pharmaceuticals, in particular to their use as inhibitors of cancer cell growth, bacterial cell growth, mammalian lipoxygenase, and to pharmaceutical compositions comprising ECO-04601 or a pharmaceutically acceptable salt or derivative thereof. Finally, the invention relates to novel polynucleotide sequences and their encoded proteins, which are involved in the biosynthesis of ECO-04601.

Abstract: Genetically engineered Streptomyces clavuligerus strains with improved capabilities to produce clavulanic acid are provided. The strains are genetically engineered by disrupting newly identified glyceraldehyde-3-phosphate dehydrogenase (GAPDH) genes. This results in an increased intracelluar pool of the clavulanic acid precursor D-glyceraldehyde-3-phosphate (D-G3P), and increased clavulanic acid production. Clavulanic acid production may be further increased by supplying arginine to the medium in which the S. clavuligerus is grown.

Abstract: The invention relates to novel perhydrolases, derived from the protease Carlsberg by amino acid exchange in positions 11, 15, 21, 38, 50, 54, 58, 77, 83, 89, 93, 96, 107, 117, 120, 134, 135, 136, 140, 147, 150, 154, 155, 160, 161, 171, 179, 180, 181, 194, 205, 208, 213, 216, 217, 238, 239, 251, 253, 257, and/or 261. The invention further relates to methods for production of said novel perhydrolases, products comprising said novel perhydrolases, particularly bodycare, haircare, shampoo, hair-dyeing, hair-bleaching, oral-care, dental-dare, dental-prosthesis-care, cosmetic, therapeutic (textile) washing, cleaning, rinsing, handwash, washing-up and dish-washing products, and corresponding applications of said novel perhydrolases.